New anecdotal paper.
Part of my wife's treatment for solitary plasmacytoma is Xgeva every 3 months. She was told to use a calcium supplement, & the oncologist regularly monitors blood levels.
It's common knowledge these days that calcium alone does not guarantee bone health, & that vitamin D is needed also. (& other things too, that have been discussed elsewhere - particularly vitamin K.)
But some here are against supplementation with vitamin D, so the following is a heads-up for those who might be on Xgeva down the road.
"Denosumab is a monoclonal antibody that has been widely used for the prevention of skeletal-related events in patients with cancer with solid tumours and bone metastases, and acts by reducing the release of calcium from bones into the bloodstream. Severe hypocalcaemia is a rare and dangerous side effect of denosumab. We present a case of a patient with metastatic prostate cancer who developed severe hypocalcaemia after receiving a single dose of denosumab. Further laboratory analysis showed that the patient had a low vitamin D level, which contributed to the development of hypocalcaemia. He required an inpatient admission for repeated doses of intravenous calcium." [1]
Ideally, one's oncologist would monitor calcidiol levels (25-D) if administering Xgeva. (& those supplementing with cholecalciferol for PCa, will already be aware of their calcidiol status - ?)
-Patrick
[1] ncbi.nlm.nih.gov/pubmed/305...
BMJ Case Rep. 2018 Dec 13;11(1). pii: e226727. doi: 10.1136/bcr-2018-226727.
Severe hypocalcaemia following denosumab in a patient with cancer with vitamin D deficiency.
Watthanasuntorn K1, Abid H1, Gnanajothy R2.
Author information
1
Internal Medicine, Bassett Healthcare Network.
2
Hematology/Oncology, Bassett Healthcare Network.
Abstract
Denosumab is a monoclonal antibody that has been widely used for the prevention of skeletal-related events in patients with cancer with solid tumours and bone metastases, and acts by reducing the release of calcium from bones into the bloodstream. Severe hypocalcaemia is a rare and dangerous side effect of denosumab. We present a case of a patient with metastatic prostate cancer who developed severe hypocalcaemia after receiving a single dose of denosumab. Further laboratory analysis showed that the patient had a low vitamin D level, which contributed to the development of hypocalcaemia. He required an inpatient admission for repeated doses of intravenous calcium.
KEYWORDS:
Cancer - See Oncology; Cancer Intervention; Prostate Cancer
PMID: 30567243 DOI: 10.1136/bcr-2018-226727